Every article, report, and earnings note where WAT appears.
A seven-stock countdown explores quality across life sciences tools, from challenged platforms to profitable analytical, diagnostic, and research franchises.
Waters is leaning into a larger life-science and diagnostics platform after its BD Biosciences and Diagnostic Solutions acquisition. Strong Q1 growth and raised guidance support a Buy, but leverage and a premium valuation keep the setup balanced.
Waters Corporation (WAT) climbs after-hours after a strong first-quarter report beat revenue guidance and lifted full-year profit outlook. The move reflects investor confidence in the company’s newly expanded business after its $18.8 billion BD biosciences and diagnostics deal.
Generate an AI-powered research report — grades, price targets, financials, and chart analysis on demand.
Generate WAT ReportCancel anytime